Management of Moderate Tricuspid Regurgitation with Normal Biventricular Function
In this patient with stable moderate tricuspid regurgitation, normal biventricular function, and no signs of right heart failure, the appropriate next step is continued surveillance with echocardiography every 1-2 years and optimization of guideline-directed medical therapy if any underlying conditions exist 1, 2.
Rationale for Conservative Management
Your patient does not meet criteria for intervention based on current guidelines. The key findings supporting surveillance include:
- Normal right ventricular function (TAPSE 3.0 cm [normal >1.7 cm], S' 17 cm/s [normal >9.5 cm/s])
- Normal right atrial pressure (IVC collapse >50%, estimated RAP 3 mmHg)
- Preserved left ventricular function (EF 57%)
- Stable disease (similar to 2022 findings)
- Only moderate TR (not severe)
Why Surgery Is Not Indicated
Current ESC/EACTS guidelines specify that surgery for isolated tricuspid regurgitation requires severe TR plus one of the following 1, 2:
- Symptomatic patients with right-sided heart failure (Class I)
- Asymptomatic patients with progressive RV dilatation or deteriorating RV function (Class IIa)
- Concomitant left-sided valve surgery being performed (Class I for severe TR, Class IIa for moderate TR with annular dilation >40 mm or >21 mm/m²)
Your patient has moderate (not severe) TR and normal RV function, therefore surgical intervention is not recommended at this time.
Surveillance Strategy
Monitor for progression with serial echocardiography every 1-2 years focusing on:
- TR severity progression to severe grade
- RV function deterioration (TAPSE <1.7 cm, S' <9.5 cm/s, or RV dilatation)
- Development of symptoms (dyspnea, peripheral edema, ascites, recurrent right heart failure)
- Pulmonary artery systolic pressure changes (PASP ≥35 mmHg associated with worse prognosis) 3
Important Prognostic Context
While your patient is currently stable, be aware that moderate TR carries prognostic significance. Recent data shows that even moderate TR with preserved LVEF has a 3-year mortality of approximately 31% and yearly mortality of 8.9% when isolated 3. However, patients with PASP <35 mmHg (like yours with normal RA pressure) have significantly better outcomes with 3-year survival of 85% 3.
Medical Management Considerations
If underlying conditions exist, optimize:
- Diuretics for any volume overload (though your patient shows no signs currently with normal IVC) 1, 2
- Guideline-directed medical therapy for heart failure if applicable 1, 4
- Rhythm control if atrial fibrillation develops 1
Critical Pitfalls to Avoid
- Do not delay intervention if TR progresses to severe with RV dysfunction—outcomes worsen significantly with advanced RV impairment 5
- Do not ignore symptoms of right heart failure (peripheral edema, ascites, hepatic congestion) even if echocardiographic parameters seem stable
- Do not miss concomitant left-sided valve disease that might warrant combined intervention 1, 2
When to Reassess for Intervention
Refer back to a Heart Valve Center if any of the following develop:
- TR progresses to severe grade
- RV dilatation or dysfunction emerges on serial imaging
- Symptoms of right heart failure develop or recur
- Patient requires left-sided valve surgery for another indication (would warrant concomitant tricuspid repair even for moderate TR with annular dilation) 1, 2
The 2025 ESC/EACTS guidelines emphasize early referral and structured evaluation when progression occurs 6, but your patient's current stable moderate TR with excellent biventricular function warrants watchful waiting rather than intervention.